Avelumab and Merkel Cell Carcinoma: Causation, FDA Warning, and Risk Context

General Health and Science Context

General health and science communication has long served as a foundation for public understanding of medical risks and therapeutic options. In this legacy context, audiences are familiar with broad discussions of immune system function, cancer biology, and the balance between treatment benefits and adverse effects. This foundational knowledge provides a necessary backdrop for more specialized inquiries into specific drug exposures and their potential consequences. As we pivot from this general health framework toward a more focused occupational exposure concern, the transition centers on the drug Avelumab, a programmed death-ligand 1 (PD-L1) inhibitor used in oncology. The target query highlights a specific association: Avelumab exposure and Merkel cell carcinoma risk, as reflected in FDA communications. This shift requires moving from abstract health principles to concrete pharmacological exposure scenarios, particularly relevant in manufacturing or clinical handling environments. The bridge concept here is straightforward: the same immune-modulating mechanisms that make Avelumab therapeutically valuable also raise questions about unintended consequences from exposure. In occupational settings, workers may encounter the drug during production, preparation, or administration. Understanding the legacy health context—how immune checkpoint inhibitors work generally—is essential before examining whether such exposure could influence Merkel cell carcinoma development. This transition thus reframes general health literacy into a specific risk assessment for those with potential contact, without venturing into mechanistic claims or citing evidence.

Bridge: From General Principles to Specific Exposure Concerns

Building on the general understanding of immune checkpoint inhibitors, we now focus on Avelumab specifically. Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). This approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Treatment Landscape

Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/36450381/). Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by ultraviolet light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The standard treatment for metastatic MCC involves the use of anti-PD-1/PD-L1 immune checkpoint inhibitors such as pembrolizumab or avelumab, which, compared with conventional chemotherapy, show better overall response rates and longer duration of responses (https://pubmed.ncbi.nlm.nih.gov/34445385/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). Furthermore, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Evidence on Avelumab Refractory Disease and Alternative Treatments

In a retrospective study conducted at three different sites in Germany, clinical and molecular data of patients with metastatic MCC refractory to avelumab and subsequently treated with combined ipilimumab and nivolumab were collected and evaluated (https://pubmed.ncbi.nlm.nih.gov/33439294/). Among five patients enrolled, three out of five responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, for avelumab-refractory patients, the available data remain limited to small case series.

FDA Warning and Causation: Avelumab as Treatment, Not Cause

The FDA warning regarding avelumab and Merkel cell carcinoma primarily concerns the drug's approved indication for treating metastatic MCC, rather than a causal link between avelumab and the development of MCC. The evidence indicates that avelumab is used as a therapeutic agent for an existing MCC diagnosis, not as a trigger for the disease. The mechanistic pathways linking avelumab to MCC are therefore not causative in the sense of inducing the cancer; rather, avelumab targets PD-L1 to enhance the immune system's ability to recognize and destroy MCC cells. The adverse effects associated with avelumab are immune-related adverse events, which can occur due to the drug's mechanism of action as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/34445385/). These events may include inflammation in various organs, but they do not include the induction of MCC. From a risk perspective, the adequacy of warnings regarding avelumab and MCC should focus on the drug's role in treating the disease, not on causing it. The FDA-approved labeling for avelumab includes information about its efficacy in metastatic MCC and potential immune-related adverse events. For affected patients, causation-related considerations are relevant only in the context of treatment response or resistance, not in terms of avelumab causing MCC. The timeline between exposure to avelumab and documented harm typically involves the onset of immune-related adverse events during or after treatment, rather than the development of MCC itself. Given that MCC is a pre-existing condition in patients receiving avelumab, the drug's association with the disease is therapeutic, not etiologic. In summary, avelumab is an approved treatment for metastatic Merkel cell carcinoma, with evidence supporting its efficacy in a subset of patients. The FDA warning pertains to the drug's use in this indication, and no evidence suggests that avelumab causes MCC. Patients who are refractory to avelumab may have limited treatment options, but alternative immune checkpoint inhibitor combinations have shown some promise in small studies. The risk narrative should emphasize that avelumab is a therapeutic agent for MCC, not a chemical trigger for the disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Avelumab cause Merkel cell carcinoma?

No, Avelumab is used to treat Merkel cell carcinoma, not cause it. The FDA warning relates to its approved indication for treating metastatic MCC. No evidence suggests Avelumab induces MCC.

What is the FDA warning about Avelumab and Merkel cell carcinoma?

The FDA warning concerns Avelumab's use in treating metastatic Merkel cell carcinoma, including information on efficacy and immune-related adverse events. It does not indicate that Avelumab causes MCC.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.